Wu James Fan, Akinola Idayat M, D'Souza Anita, Cusatis Rachel
Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Clin Lymphoma Myeloma Leuk. 2025 Jul 11. doi: 10.1016/j.clml.2025.07.002.
We investigated autologous stem cell transplantation (ASCT) barriers in a single-center qualitative study by interviewing patients with multiple myeloma (MM), transplant physicians (TPs), and referring physicians (RPs).
Patients with MM and referred for ASCT evaluation between January 01, 2021 and December 31, 2022, TPs from 2 Wisconsin transplant centers, and RPs from rural and urban Wisconsin were recruited. Interviews were conducted using a semi-structured interview guide focused on ASCT barriers. Transcripts were double-coded and reviewed. An initial codebook with prespecified themes based on the interview guide was developed and iteratively revised.
Eighteen patients, 5 TPs, and 4 RPs were interviewed. Four major ASCT barriers themes were identified across all stakeholders: caregiver support, patient concerns and knowledge, financial toxicity, and logistics. Unique themes included social support by patients and ASCT referral by physicians. Lacking caregiver support was more common among single, childless, and socially/geographically isolated patients. Patients were most concerned about side effects, long hospital stays, and quality of life. Patients used online websites and support groups to gain knowledge and support. While most patients experienced financial toxicity, care costs were rarely discussed. Distance from transplant center, transportation, and care coordination were barriers. Referrals from community oncologists are a major barrier. Patients never seen at a transplant center may have the most barriers.
This qualitative study of both patients and physicians investigating barriers to access to ASCT in MM, provides a much-needed multistakeholder perspective. Interventional strategies targeting key barriers will be critical in improving ASCT utilization in MM.
我们通过对多发性骨髓瘤(MM)患者、移植医生(TPs)和转诊医生(RPs)进行访谈,在一项单中心定性研究中调查了自体干细胞移植(ASCT)的障碍。
招募了2021年1月1日至2022年12月31日期间因ASCT评估而转诊的MM患者、来自威斯康星州2个移植中心的TPs以及来自威斯康星州农村和城市的RPs。访谈采用聚焦于ASCT障碍的半结构化访谈指南进行。访谈记录进行了双重编码和审查。基于访谈指南制定了一个带有预先指定主题的初始编码手册,并进行了反复修订。
共访谈了18名患者、5名TPs和4名RPs。在所有利益相关者中确定了四个主要的ASCT障碍主题:护理人员支持、患者担忧和知识、经济毒性以及后勤保障。独特的主题包括患者的社会支持和医生的ASCT转诊。在单身、无子女以及社会/地理上孤立的患者中,缺乏护理人员支持更为常见。患者最担心的是副作用、住院时间长和生活质量。患者通过在线网站和支持小组获取知识和支持。虽然大多数患者都经历了经济毒性,但很少讨论护理费用。距离移植中心的距离、交通和护理协调是障碍。社区肿瘤学家的转诊是一个主要障碍。从未在移植中心就诊过的患者可能障碍最多。
这项对患者和医生进行的关于MM患者接受ASCT障碍的定性研究,提供了急需的多利益相关者视角。针对关键障碍的干预策略对于提高MM患者ASCT的利用率至关重要。